This DEFA14A likely accompanies a definitive proxy statement (DEF14A) or preliminary materials related to an activist/dissident proxy contest. The cross-filing amplifiers strongly suggest an ongoing campaign with potential board changes or shareholder proposals. Traders should locate the related DEF14A or preliminary proxy for specific vote items and activist demands.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $0.8991entry
- T+1 · 5mo ago −2.00%α −2.78% · $0.8811
- T+5 · 4mo ago −5.89%α −7.28% · $0.8461
- T+20 · 4mo ago −24.21%α −23.93% · $0.6814
- T+60 · 8w ago +1.21%α −3.17% · $0.9100
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology Corp filed a DEFA14A, which is additional definitive proxy soliciting material. The document body is almost entirely comprised of encoded/compressed graphical data and contains no readable text describing specific proposals, shareholder votes, or activist demands. With no substantive content available, the filing appears to be a routine cover-page-only submission of graphic exhibits related to a proxy solicitation.
Key Facts
- Filed as DEFA14A (additional definitive proxy soliciting materials) on 2026-06-26
- Filer is PDS Biotechnology Corp, a pharmaceutical preparations company
- Document text contains only EDGAR headers, a Schedule 14A cover page, and two large binary graphic files (JPG images)
- No textual details on meeting agenda, proposals, or activist demands were found in the filing
- Evidence of an ongoing dissident proxy campaign indicated by cross-filing actuarial verdicts, which universally amplified the combination of 'dissident-proxy-activist-context' with preliminary, executive change, and DEF14A contexts
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- No substantive content in this filing limits actionable analysis
- Activists/dissidents may be seeking board seats or strategic changes that could affect company direction
- Proxy fights in small-cap biotechs (market cap ~$49M) can lead to significant stock volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-026570 |
| Document: 0001140361-26-026570-index-headers.html | 0001140361-26-026570 |
| Document: 0001140361-26-026570-index.html | 0001140361-26-026570 |
| Document: 0001140361-26-026570.txt | 0001140361-26-026570 |
Track record
28 reports on PDSB
7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers